

Abstract

The present invention relates to the field of medical biology, and discloses a single domain antibody and derivative proteins thereof against programmed death ligand (PDL1). In particular, the present invention discloses a
5 programmed death ligand 1 (PDL1) binding molecular and the use thereof, especially the use for treating and/or preventing or diagnosing PDL1 relevant diseases such as tumor.